Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Rare Histological Subtypes of Advanced NSCLC
NCT03976518Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- May 2019
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started May 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03976518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976518.